WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a softgel capsule containing a nonaqueous, lipid-based solution of the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof, the compound of Formula (I), or a pharmaceutically acceptable salt thereof being present in a range of from about 30 mg to about 480 mg, and



(**I**)

(i) abiraterone acetate, wherein the abiraterone acetate is present in the composition in an amount ranging from 500 mg to 1000 mg; and

(ii) prednisone, wherein the prednisone is present in the composition in a therapeutically effective amount.

2. The pharmaceutical composition of claim 1, wherein the nonaqueous, lipid-based solution of the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof, comprises: the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof, vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate NF (Vitamin E TPGS),

polyethylene glycol 400 NF/EP (PEG 400), glycerol monocaprylocaprate EP and caprylocaproyl macroglycerides EP/NF.

3. The pharmaceutical composition of claim 1, wherein the nonaqueous, lipid-based solution the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof, comprises about 3% of the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the softgel capsule shell comprises gelatin NF/EP, a 50:50 sorbitol/glycerin blend USP/EP, and purified water USP/EP.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein a single unit dosage comprises about 30 mg of the compound of Formula (**I**), or a pharmaceutically acceptable salt thereof,



(**I**)

6. A pharmaceutical composition comprising:

(a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, present in the composition in a range of from 30 mg to 480 mg;



(I)

(b) a pharmaceutically acceptable carrier or excipient;

(c) abiraterone acetate; and

(d) prednisone.

7. The pharmaceutical composition of claim 6, wherein abiraterone acetate is present in the composition in an amount ranging of from about 500 mg to about 1000 mg.

8. The pharmaceutical composition of claim 6 or claim 7, wherein the prednisone is present in the composition in a therapeutically effective amount.

9. The pharmaceutical composition of claim 6 or claim 7, wherein the prednisone is present in the composition in an amount of about 5 mg.

10. The pharmaceutical composition of any one of claims 6 to 9, wherein the composition is a tablet.

11. The pharmaceutical composition of claim 10, wherein the tablet contains 30 mg to 60 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

12. The pharmaceutical composition of any one of claims 6 to 9, wherein the composition is a softgel capsule.

13. The pharmaceutical composition of claim 12, wherein the softgel capsule contains 30 mg to 60 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

14. Use of a compound of Formula (**I**),



(I)

or a pharmaceutically acceptable salt thereof, in

the manufacture of a medicament for treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a human patient, wherein the medicament is to be administrated orally at a dose of about 30 mg per day to about 480 mg per day, preferably at a dose of about 240 mg per day of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the human patient in need of such treatment, and wherein the compound of Formula (I) is to be administered in combination with:

(a) abiraterone acetate; and

(b) prednisone.

15. The pharmaceutical composition of claim 2, further comprising one or more of:

4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methylbenzamide;

4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-thioxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;

methyl 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluorobenzoate;

4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluorobenzoic acid;

4-(7-(6-cyano-5-(difluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluoro-N-methylbenzamide;

4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluoro-N-methylbenzothioamide;

2-chloro-4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,- 7-diazaspiro[3.4]octan-5-yl)-N-methylbenzamide;

5-amino-3-(trifluoromethyl)picolinonitrile;

1-((4-(methylcarbamoyl)phenyl)amino)cyclobutanecarboxylic acid;

1-(3-fluoro-4-(methylcarbamoyl)phenylamino)cyclobutanecarboxylic acid;

or a pharmaceutically acceptable salt thereof.

16. Use of a compound of Formula (**I**),



(I)

or a pharmaceutically acceptable salt thereof, in
the manufacture of a medicament for treating post-abiraterone acetate treated metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a human patient, wherein the medicament is to be administered orally at a dose of about 30 mg per day to about 480 mg per day, preferably at a dose of about 240 mg per day of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the human patient in need of such treatment, and wherein the compound of Formula (I) is to be administered in combination with:

(a) abiraterone acetate; and

(b) prednisone.

17. The use of claim 14 or claim 16, wherein the abiraterone acetate is to be administered at a dose in a range of from 500 mg per day to 1000 mg per day.

18. The use of claim 14 or claim 16, wherein the prednisone is to be administered at a therapeutically effective amount.

19. The use of claim 14 or claim 16, wherein the prednisone is to be administered at a dose of about 5 mg twice per day.